Relapsed and Refractory CD5-Expressing T Cell Lymphomas - Pipeline Insight, 2022
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Relapsed and Refractory CD5-Expressing T Cell Lymphomas - Pipeline Insight, 2022” report provides comprehensive insights about 2+ companies and 3+ pipeline drugs in Relapsed and Refractory CD5-Expressing T Cell Lymphomas pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Relapsed and Refractory CD5-Expressing T Cell Lymphomas: Overview
Relapsed and Refractory CD5-Expressing T Cell Lymphomas refers to lymphoma that reappears or grows again after a period of remission or the lymphoma that does not respond to available therapy treatment (meaning that the cancer cells continue to grow). There is no consensus exists on the best therapeutic strategy for relapsed/refractory Peripheral T-Cell Lymphoma (PTCL). CD5 is one of the most common surface markers of malignant T cells, expressed in around 80% of TALLs (T cell acute lymphoblastic leukemia) and T?cell lymphomas. CD5 as a receptor regulates T?cell development and function, acting as a negative regulator of TCR?CD3 signaling. CD5+ T cell lymphomas are a subset of lymphomas that are positive for the surface protein CD5. CD5 is a T cell, B1-a cell, and B-CLL receptor first described over 30 years ago that has been used as surface marker to identify both human and murine cell populations. CD5 is a potentially good target for a T?cell based CAR therapy.
Report Highlights
This segment of the Relapsed and Refractory CD5-Expressing T Cell Lymphomas report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Relapsed and Refractory CD5-Expressing T Cell Lymphomas Emerging Drugs
Further product details are provided in the report……..
Relapsed and Refractory CD5-Expressing T Cell Lymphomas: Therapeutic Assessment
This segment of the report provides insights about the different Relapsed and Refractory CD5-Expressing T Cell Lymphomas drugs segregated based on following parameters that define the scope of the report, such as:
Relapsed and Refractory CD5-Expressing T Cell Lymphomas: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Relapsed and Refractory CD5-Expressing T Cell Lymphomas therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsed and Refractory CD5-Expressing T Cell Lymphomas drugs.
Relapsed and Refractory CD5-Expressing T Cell Lymphomas Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Relapsed and Refractory CD5-Expressing T Cell Lymphomas - Pipeline Insight, 2022” report provides comprehensive insights about 2+ companies and 3+ pipeline drugs in Relapsed and Refractory CD5-Expressing T Cell Lymphomas pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Relapsed and Refractory CD5-Expressing T Cell Lymphomas: Overview
Relapsed and Refractory CD5-Expressing T Cell Lymphomas refers to lymphoma that reappears or grows again after a period of remission or the lymphoma that does not respond to available therapy treatment (meaning that the cancer cells continue to grow). There is no consensus exists on the best therapeutic strategy for relapsed/refractory Peripheral T-Cell Lymphoma (PTCL). CD5 is one of the most common surface markers of malignant T cells, expressed in around 80% of TALLs (T cell acute lymphoblastic leukemia) and T?cell lymphomas. CD5 as a receptor regulates T?cell development and function, acting as a negative regulator of TCR?CD3 signaling. CD5+ T cell lymphomas are a subset of lymphomas that are positive for the surface protein CD5. CD5 is a T cell, B1-a cell, and B-CLL receptor first described over 30 years ago that has been used as surface marker to identify both human and murine cell populations. CD5 is a potentially good target for a T?cell based CAR therapy.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Relapsed and Refractory CD5-Expressing T Cell Lymphomas R&D. The therapies under development are focused on novel approaches for Relapsed and Refractory CD5-Expressing T Cell Lymphomas.
This segment of the Relapsed and Refractory CD5-Expressing T Cell Lymphomas report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Relapsed and Refractory CD5-Expressing T Cell Lymphomas Emerging Drugs
- Anti-CD5 CAR T-cell therapy: iCell Gene Therapeutics
- MT-101: Myeloid Therapeutics
Further product details are provided in the report……..
Relapsed and Refractory CD5-Expressing T Cell Lymphomas: Therapeutic Assessment
This segment of the report provides insights about the different Relapsed and Refractory CD5-Expressing T Cell Lymphomas drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Relapsed and Refractory CD5-Expressing T Cell Lymphomas
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Relapsed and Refractory CD5-Expressing T Cell Lymphomas: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Relapsed and Refractory CD5-Expressing T Cell Lymphomas therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsed and Refractory CD5-Expressing T Cell Lymphomas drugs.
Relapsed and Refractory CD5-Expressing T Cell Lymphomas Report Insights
- Relapsed and Refractory CD5-Expressing T Cell Lymphomas Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Relapsed and Refractory CD5-Expressing T Cell Lymphomas drugs?
- How many Relapsed and Refractory CD5-Expressing T Cell Lymphomas drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Relapsed and Refractory CD5-Expressing T Cell Lymphomas?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Relapsed and Refractory CD5-Expressing T Cell Lymphomas therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Relapsed and Refractory CD5-Expressing T Cell Lymphomas and their status?
- What are the key designations that have been granted to the emerging drugs?
- Myeloid Therapeutics
- iCell Gene Therapeutics
- MT-101
- Anti-CD5 CAR T-cell therapy
Introduction
Executive Summary
Relapsed and Refractory CD5-Expressing T Cell Lymphomas: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Relapsed and Refractory CD5-Expressing T Cell Lymphomas – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Relapsed and Refractory CD5-Expressing T Cell Lymphomas companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Relapsed and Refractory CD5-Expressing T Cell Lymphomas Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Anti-CD5 CAR T-cell therapy: iCell Gene Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Relapsed and Refractory CD5-Expressing T Cell Lymphomas Key Companies
Relapsed and Refractory CD5-Expressing T Cell Lymphomas Key Products
Relapsed and Refractory CD5-Expressing T Cell Lymphomas- Unmet Needs
Relapsed and Refractory CD5-Expressing T Cell Lymphomas- Market Drivers and Barriers
Relapsed and Refractory CD5-Expressing T Cell Lymphomas- Future Perspectives and Conclusion
Relapsed and Refractory CD5-Expressing T Cell Lymphomas Analyst Views
Relapsed and Refractory CD5-Expressing T Cell Lymphomas Key Companies
Appendix
Executive Summary
Relapsed and Refractory CD5-Expressing T Cell Lymphomas: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Relapsed and Refractory CD5-Expressing T Cell Lymphomas – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Relapsed and Refractory CD5-Expressing T Cell Lymphomas companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Relapsed and Refractory CD5-Expressing T Cell Lymphomas Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Anti-CD5 CAR T-cell therapy: iCell Gene Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Relapsed and Refractory CD5-Expressing T Cell Lymphomas Key Companies
Relapsed and Refractory CD5-Expressing T Cell Lymphomas Key Products
Relapsed and Refractory CD5-Expressing T Cell Lymphomas- Unmet Needs
Relapsed and Refractory CD5-Expressing T Cell Lymphomas- Market Drivers and Barriers
Relapsed and Refractory CD5-Expressing T Cell Lymphomas- Future Perspectives and Conclusion
Relapsed and Refractory CD5-Expressing T Cell Lymphomas Analyst Views
Relapsed and Refractory CD5-Expressing T Cell Lymphomas Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Relapsed and Refractory CD5-Expressing T Cell Lymphomas
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Relapsed and Refractory CD5-Expressing T Cell Lymphomas
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Relapsed and Refractory CD5-Expressing T Cell Lymphomas
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Relapsed and Refractory CD5-Expressing T Cell Lymphomas
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
